Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.

Eggermont AM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Boers-Sonderen M, Di Giacomo AM, van den Eertwegh AJ, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Lorigan P, Grebennik D, Kreplere C, Marreaud S, Suciu S, Robert C

Open source

DOI: 10.1016/j.ejca.2024.114327
Published: 2024 Nov
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2024.114327,
  title = {Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.},
  author = {Eggermont AM and Kicinski M and Blank CU and Mandala M and Long GV and Atkinson V and Dalle S and Haydon A and Meshcheryakov A and Khattak A and Carlino MS and Sandhu S and Larkin J and Puig S and Ascierto PA and Rutkowski P and Schadendorf D and Boers-Sonderen M and Di Giacomo AM and van den Eertwegh AJ and Grob JJ and Gutzmer R and Jamal R and van Akkooi ACJ and Lorigan P and Grebennik D and Kreplere C and Marreaud S and Suciu S and Robert C},
  year = {2024},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2024.114327},
  url = {https://doi.org/10.1016/j.ejca.2024.114327}
}

RIS

TY  - JOUR
TI  - Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.
AU  - Eggermont AM
AU  - Kicinski M
AU  - Blank CU
AU  - Mandala M
AU  - Long GV
AU  - Atkinson V
AU  - Dalle S
AU  - Haydon A
AU  - Meshcheryakov A
AU  - Khattak A
AU  - Carlino MS
AU  - Sandhu S
AU  - Larkin J
AU  - Puig S
AU  - Ascierto PA
AU  - Rutkowski P
AU  - Schadendorf D
AU  - Boers-Sonderen M
AU  - Di Giacomo AM
AU  - van den Eertwegh AJ
AU  - Grob JJ
AU  - Gutzmer R
AU  - Jamal R
AU  - van Akkooi ACJ
AU  - Lorigan P
AU  - Grebennik D
AU  - Kreplere C
AU  - Marreaud S
AU  - Suciu S
AU  - Robert C
PY  - 2024
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2024.114327
UR  - https://doi.org/10.1016/j.ejca.2024.114327
ER  -

APA

AM, E., M, K., CU, B., M, M., GV, L., V, A., S, D., A, H., A, M., A, K., MS, C., S, S., J, L., S, P., PA, A., P, R., D, S., M, B., AM, D. G., AJ, V. D. E., JJ, G., R, G., R, J., ACJ, V. A., P, L., D, G., C, K., S, M., S, S., & C, R. (2024). Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2024.114327

Source records

pubmed · retrieved 2026-09-26T19:52:35.417Z